Search results for "Perazine"

showing 10 items of 240 documents

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, mu…

2013

Contains fulltext : 118365.pdf (Publisher’s version ) (Closed access) BACKGROUND: Until now, only imatinib and sunitinib have proven clinical benefit in patients with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression. We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib. METHODS: We did this phase 3 trial at 57 hospitals in 17 countries. Patients with histologically confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib were rando…

OncologyMaleIndolesPyridinesSettore MED/06 - Oncologia MedicaSU11248MedizinPiperazineslaw.inventionchemistry.chemical_compoundRandomized controlled triallawClinical endpointSunitinibTreatment Failureregorafenib; gastrointestinal stromal tumours; imatinib and sunitinibGastrointestinal Neoplasmseducation.field_of_studyGiSTSunitinibKITAge-related aspects of cancer Quality of hospital and integrated care [ONCOL 2]General MedicineMiddle AgedSurvival RateBenzamidesImatinib MesylateFemaleADJUVANT IMATINIBTYROSINE KINASE INHIBITORColorectal NeoplasmsLife Sciences & Biomedicinemedicine.drugGROWTH-FACTORmedicine.medical_specialtyGastrointestinal Stromal TumorsPopulationMESYLATEAntineoplastic AgentsIMATINIBArticleMECHANISMSMedicine General & InternalDouble-Blind MethodTranslational research [ONCOL 3]General & Internal MedicineRegorafenibInternal medicineMANAGEMENTmedicineHumansPyrroleseducationProtein Kinase InhibitorsAgedScience & TechnologyGASTROINTESTINAL STROMAL TUMOURSimatinib and sunitinibMUTATIONSbusiness.industryPhenylurea CompoundsGIST regorafenib imatinib sunitinib phase III trialSurgeryClinical trialImatinib mesylatePyrimidineschemistryregorafenibbusinessRESISTANCE
researchProduct

Lack of everolimus diffusion in pleural fluid during pleural progression of breast cancer: A case report

2020

Background We report here a case where no everolimus pleural diffusion was evidenced at the same time of pleural progression of a metastatic breast cancer treated with everolimus and exemestane. Case description A 69-year-old woman was diagnosed in October 2006 with stage III invasive ductal breast adenocarcinoma. After nine months of everolimus and exemestane treatment, she presented with a pleural progression. Everolimus concentration was measured in blood and in pleural fluid. Residual blood concentration was at 9.1 ng/mL, while no everolimus was observed in the pleural fluid. Management and outcome Due to inefficacy of everolimus in this patient, she was switched to palbociclib and fulv…

Oncologymedicine.medical_specialtyPyridinesBreast NeoplasmsPiperazines03 medical and health sciences0302 clinical medicineBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)EverolimusAgedEverolimusbusiness.industrymedicine.diseaseMetastatic breast cancerAndrostadienesOncology030220 oncology & carcinogenesisDisease ProgressionPleural fluidFemalebusiness030215 immunologymedicine.drugJournal of Oncology Pharmacy Practice
researchProduct

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK …

2013

Background: Combined inhibition of platelet-derived growth factor receptor beta signalling and vascular endothelial growth factor promotes vascular normalisation in preclinical models and may lead to increased delivery of chemotherapy to tumour tissue. This phase I/II trial assessed the safety and efficacy of capecitabine plus oxaliplatin (XELOX) plus bevacizumab and imatinib in the first-line treatment of patients with metastatic colorectal cancer. Methods: Two dose levels (I/II) were defined: capecitabine 850/1000 mg m−2 twice daily on days 1–14; oxaliplatin 100/130 mg m−2 on day 1; bevacizumab 7.5 mg kg−1 on day 1; imatinib 300 mg day−1 on days 1–21 every 21 days. The primary study endpo…

OncologysafetyAdultMaleCancer Researchmedicine.medical_specialtyBevacizumabOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentcolorectal cancerbevacizumabAntibodies Monoclonal HumanizedDeoxycytidineDisease-Free SurvivalDrug Administration SchedulePiperazinesCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansProspective StudiesCapecitabineAgedAged 80 and overChemotherapybusiness.industrySunitiniboxaliplatinMiddle Agedmedicine.diseaseSurgeryOxaliplatinImatinib mesylatePyrimidinesTreatment OutcomeOncologyimatinibFluorouracilBenzamidesClinical StudyImatinib MesylateFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drugBritish Journal of Cancer
researchProduct

No carrier-added nucleophilic aromatic radiofluorination using solid phase supported arenediazonium sulfonates and 1-(aryldiazenyl)piperazines

2012

Abstract This Letter concerns the investigation of a solid phase based method for no carrier-added nucleophilic [ 18 F]fluorination of aromatic compounds via de-diazofluorination. Initial screening of reaction conditions was conducted using soluble analogues, that is, substituted benzenediazonium tosylates and 1-(phenyldiazenyl)piperazines in solution. This was followed by translation of the principle conditions to solid phase bound analogues. A variety of substituted aryldiazonium cations were immobilised using a sulfonate functionalised ion exchange resin and labelled with [ 18 F]fluoride ion by Balz–Schiemann like thermal decomposition in the presence of no carrier-added [ 18 F]fluoride …

Organic ChemistryThermal decompositionBiochemistryPiperazinechemistry.chemical_compoundSulfonatechemistryNucleophileCovalent bondDrug DiscoveryPolymer chemistryOrganic chemistryBalz–Schiemann reactionIon-exchange resinFluorideTetrahedron Letters
researchProduct

Pathway-specificity in N-methyl-d-aspartate receptor-mediated synaptic inputs onto subplate neurons

2007

The subplate plays an important role in forming neuronal connections during early cortical development. We characterized by the use of whole-cell and cell-attached patch-clamp recordings in coronal brain slices from newborn mice (postnatal day [P] 0-3) the functional properties of two major pathways onto subplate neurons (SPn), the thalamocortical and the intra-subplate synaptic input. The two afferent pathways were stimulated extracellularly with bipolar electrodes placed in the thalamus and the subplate, respectively. Synaptically evoked and pharmacologically isolated N-methyl-d-aspartate receptor (NMDAR) -mediated responses with an onset latency of approximately 6 ms could be reliably re…

Patch-Clamp TechniquesThalamusIn Vitro TechniquesBiologyReceptors N-Methyl-D-AspartatePiperazinesMicechemistry.chemical_compoundThalamusSubplateNeural PathwaysmedicineIfenprodilAnimals6-Cyano-7-nitroquinoxaline-23-dioneCerebral CortexNeuronsGeneral NeuroscienceAge FactorsGlutamate receptorExcitatory Postsynaptic PotentialsDose-Response Relationship RadiationElectric StimulationElectrophysiologymedicine.anatomical_structureAnimals NewbornchemistrySynapsesExcitatory postsynaptic potentialNMDA receptorNeuronExcitatory Amino Acid AntagonistsNeuroscienceNeuroscience
researchProduct

Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management

2013

Dermatofibrosarcoma protuberans (DFSP) is a rare superficial tumor characterized by high rates of local recurrence and low risk of metastasis. DFSP occurs most commonly on the trunk and proximal extremities, affects all races, and often develops between the second and fifth decade of life. The tumor grows slowly, typically over years. Histologically, several variants of DFSP have been described and should be well characterized to avoid misdiagnosis with other tumors. These include pigmented (Bednar tumor), myxoid, myoid, granular cell, sclerotic, atrophic DFSP, giant cell fibroblastoma, and DFSP with fibrosarcomatous areas. Of all these variants, only the DFSP with fibrosarcomatous areas is…

Pathologymedicine.medical_specialtySkin Neoplasmsmedicine.medical_treatmentAntineoplastic AgentsPiperazinesTranslocation GeneticPathology and Forensic MedicineMetastasismedicineDermatofibrosarcoma protuberansHumansbusiness.industryStandard treatmentWide local excisionDermatofibrosarcomaImatinibGiant-cell fibroblastomaMohs Surgerymedicine.diseaseCombined Modality TherapyDermatologyPyrimidinesImatinib mesylateBenzamidesImatinib MesylateNeoplasm Recurrence LocalDifferential diagnosisbusinessmedicine.drugSeminars in Diagnostic Pathology
researchProduct

DMPP and the adrenergic nerve terminal: mechanisms of noradrenaline release from vesicular and extravesicular compartments.

1977

DMPP (1,1-dimethyl-4-phenylpiperazine) in various concentrations between 1.6×10−6 M and 6.2×10−5 M was infused into isolated rabbit hearts to study the neuronal release and uptake of noradrenaline.

PharmacologyNeuronsmedicine.medical_specialtySympathetic Nervous SystemChemistryMyocardiumPharmacology toxicologyAdrenergicMyocardium metabolismHeartGeneral MedicinePharmacologyIn Vitro TechniquesPiperazinesNorepinephrineEndocrinologyInternal medicinemedicineAnimalsNorepinephrine metabolismRabbitsDimethylphenylpiperazinium IodideNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Prevention of the acute neurotoxic effects of phenytoin on rat peripheral nerve by H7, an inhibitor of protein kinase C.

1992

Abstract The neurotoxic effects of a single dose of phenytoin (150 mg/kg body weight) alone or 30 min after H7 (a protein kinase C inhibitor) injection (20 mg/kg body weight) were investigated in terms of peripheral neuromuscular function and Na + ,K + -ATPase activity of the sciatic nerve. This intraperitoneal injection of phenytoin induced complete blockade of muscle action potentials in the dorsal segmental muscles of the rat tail evoked by electric stimulation of the caudal nerve and a 40% decrease in the Na + ,K + -ATPase activity of the rat sciatic nerve when compared with control values, measured as the difference between total and ouabain-insensitive ATPase activity. Prior administr…

PhenytoinMalemedicine.medical_treatmentIntraperitoneal injectionPharmacologyToxicologyNeuromuscular junctionPiperazines1-(5-Isoquinolinesulfonyl)-2-MethylpiperazinemedicineAnimalsPeripheral NervesNa+/K+-ATPaseRats WistarProtein kinase CProtein Kinase CbiologyChemistryIsoquinolinesSciatic NerveElectric StimulationRatsElectrophysiologymedicine.anatomical_structureAnticonvulsantEnzyme inhibitorAnesthesiaPhenytoinbiology.proteinSciatic nerveSodium-Potassium-Exchanging ATPaseInjections Intraperitonealmedicine.drugToxicology
researchProduct

Glass-Forming Nonsymmetric DWKdyes with 5,5,5-Triphenylpentyl and Piparazine Moieties for Lightamplification Studies

2018

This work has been supported by the European Regional Development Fund within the Activity 1.1.1.2 “Post-doctoral Research Aid” of the Specific Aid Objective 1.1.1 “To increase the research and innovative capacity of scientific institutions of Latvia and the ability to attract external financing, investing in human resources and infrastructure” of the Operational Programme “Growth and Employment” (No. 1.1.1.2/VIAA/1/16/035). Financial support provided by A. Riekstins SIA “Mikrotīkls” donation, administered by the University of Latvia is greatly appreciated. There are no conflicts of interest to declare.

PhotoluminescenceInfraredmolecular glasses02 engineering and technology010402 general chemistry01 natural sciencesamplified spontaneous emissionchemistry.chemical_compoundPolymer chemistry:NATURAL SCIENCES:Physics [Research Subject Categories]MoleculeThermal stability4 H -pyran-4-ylideneamplified spontaneous emission; laser dyes; 4H-pyran-4-ylidene; triphenyl moieties; piperazine moieties; molecular glasseslaser dyesMalononitrileRenewable Energy Sustainability and the Environmentpiperazine moieties021001 nanoscience & nanotechnologyAtomic and Molecular Physics and Optics0104 chemical sciencesPiperazinechemistryCovalent bond0210 nano-technologyLuminescencetriphenyl moieties
researchProduct

Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia.

2008

Although imatinib mesylate (IM) has revolutionized the treatment of chronic myeloid leukemia (CML), some patients develop resistance with progression of leukemia. Alternative or additional targeting of signaling pathways deregulated in bcr-abl-driven CML cells may provide a feasible option for improving clinical response and overcoming resistance. In this study, we show that carboxyamidotriazole (CAI), an orally bioavailable calcium influx and signal transduction inhibitor, is equally effective in inhibiting the proliferation and bcr-abl dependent- and independent-signaling pathways in imatinib-resistant CML cells. CAI inhibits phosphorylation of cellular proteins including STAT5 and CrkL a…

PhysiologyMAP Kinase Signaling SystemClinical BiochemistryFusion Proteins bcr-ablDown-RegulationApoptosisSignal transduction inhibitorPharmacologyPiperazineschemistry.chemical_compoundhemic and lymphatic diseasesCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansEnzyme InhibitorsPhosphotyrosineCMLneoplasmsIn Situ Hybridization FluorescenceChronic Myelogenous LeukemiaCell ProliferationCarboxyamidotriazolebusiness.industryCAIMyeloid leukemiaImatinibCell BiologyTriazolesmedicine.diseaseCRKLEnzyme ActivationGene Expression Regulation NeoplasticLeukemiaImatinib mesylatePyrimidineschemistryDrug Resistance NeoplasmMolecular ProbesBenzamidesimatinib resistanceImatinib Mesylateras ProteinsCML; imatinib resistance; CAICarboxyamidotriazolebusinesssignal transductionChronic myelogenous leukemiamedicine.drugJournal of cellular physiology
researchProduct